益方生物：12月8日召开董事会会议

Group 1 - The core viewpoint of the article highlights the recent developments in Yifang Biotechnology, including the announcement of its board meeting and the company's financial performance in the pharmaceutical manufacturing sector [1] - Yifang Biotechnology's revenue composition for the year 2024 is reported to be 100% from the pharmaceutical manufacturing industry [1] - As of the report, Yifang Biotechnology has a market capitalization of 16.3 billion yuan [1] Group 2 - The article also discusses a concerning trend in the pharmaceutical industry, specifically the abuse of pregabalin leading to addiction cases, marking the first report of such incidents in the domestic market [1] - It mentions vulnerabilities in online platforms that allow the purchase of medications without proper medical records, raising questions about regulatory oversight [1] - The classification of pregabalin and the need for scientific evaluation regarding its regulation are emphasized as critical issues [1]